Daniel P Eisenberg1, Grisel Lopez2, Michael D Gregory1, Karen F Berman1, Ellen Sidransky2. 1. Clinical and Translational Neuroscience Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA. 2. Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
BACKGROUND: Mutations in GBA1 are a common genetic risk factor for parkinsonism; however, penetrance is incomplete, and biomarkers of future progression to parkinsonism are needed. Both nigral sonography and striatal [18 F]-FDOPA PET assay dopamine system health, but their utility and coherence in this context are unclear. OBJECTIVE: The aim of this study is to evaluate the utility and coherence of these modalities in GBA1-associated parkinsonism. METHODS: A total of 34 patients with GBA1 mutations (7 with parkinsonism) underwent both transcranial studies for substantia nigra echogenicity and [18 F]-FDOPA PET to determine striatal tracer-specific uptake (Ki ). RESULTS: Larger nigral echogenic areas and reduced striatal Ki were exclusively observed in parkinsonian patients. Sonographic and PET measurements showed strong inverse correlations but only in individuals with clinical parkinsonism. CONCLUSIONS: Close correspondence between nigral echogenicity and striatal presynaptic dopamine synthesis capacity observed only in GBA1 carriers with parkinsonism provides validation that these two modalities may conjointly capture aspects of the biology underlying clinical parkinsonism but raises questions about their utility as predictive tools in at-risk subjects.
BACKGROUND: Mutations in GBA1 are a common genetic risk factor for parkinsonism; however, penetrance is incomplete, and biomarkers of future progression to parkinsonism are needed. Both nigral sonography and striatal [18 F]-FDOPA PET assay dopamine system health, but their utility and coherence in this context are unclear. OBJECTIVE: The aim of this study is to evaluate the utility and coherence of these modalities in GBA1-associated parkinsonism. METHODS: A total of 34 patients with GBA1 mutations (7 with parkinsonism) underwent both transcranial studies for substantia nigra echogenicity and [18 F]-FDOPA PET to determine striatal tracer-specific uptake (Ki ). RESULTS: Larger nigral echogenic areas and reduced striatal Ki were exclusively observed in parkinsonian patients. Sonographic and PET measurements showed strong inverse correlations but only in individuals with clinical parkinsonism. CONCLUSIONS: Close correspondence between nigral echogenicity and striatal presynaptic dopamine synthesis capacity observed only in GBA1 carriers with parkinsonism provides validation that these two modalities may conjointly capture aspects of the biology underlying clinical parkinsonism but raises questions about their utility as predictive tools in at-risk subjects.
Authors: N Tayebi; K J Reissner; E K Lau; B K Stubblefield; A C Klineburgess; B M Martin; E Sidransky Journal: Pediatr Res Date: 1998-05 Impact factor: 3.756
Authors: Luigi Zecca; Daniela Berg; Thomas Arzberger; Petra Ruprecht; Wolf D Rausch; Massimo Musicco; Davide Tampellini; Peter Riederer; Manfred Gerlach; Georg Becker Journal: Mov Disord Date: 2005-10 Impact factor: 10.338
Authors: Petra Bártová; Otakar Kraft; Jaromír Bernátek; Martin Havel; Pavel Ressner; Kateřina Langová; Roman Herzig; David Skoloudík Journal: Ultrasound Med Biol Date: 2014-10 Impact factor: 2.998
Authors: J M Hagenah; I R König; B Becker; R Hilker; M Kasten; K Hedrich; P P Pramstaller; C Klein; G Seidel Journal: J Neurol Date: 2007-10-15 Impact factor: 4.849
Authors: Sebastian Heinzel; Benjamin Roeben; Yoav Ben-Shlomo; Stefanie Lerche; Guido Alves; Paolo Barone; Stefanie Behnke; Henk W Berendse; Bastiaan R Bloem; David Burn; Richard Dodel; Donald G Grosset; Michele Hu; Meike Kasten; Rejko Krüger; Marcello Moccia; Brit Mollenhauer; Wolfgang Oertel; Ulrike Suenkel; Uwe Walter; Karin Wirdefeldt; Inga Liepelt-Scarfone; Walter Maetzler; Daniela Berg Journal: Front Aging Neurosci Date: 2016-06-22 Impact factor: 5.750